BURST CME™: Taking ALS Management to the Next Level
March 27, 2023
March 27, 2024
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward neurologists. Neuromuscular specialists, specialty nurse practitioners, physician assistants, nurses, and other health care practitioners involved in the care of patients with amyotrophic lateral sclerosis (ALS) are also invited to participate.
The neurodegeneration characteristic of ALS progressively affects a patient’s body regions, frequently limiting survival to 2 to 5 years after disease onset. The aims of management are to extend quality of life and slow disease progression. Patients with ALS have had limited disease-modifying treatment options, but recent availability of new therapies and continuing development of investigational agents is leading to exciting advances in ALS care.
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of ALS with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of supportive care and of current and investigational therapies will be presented in a multimedia format, including a series of audio interviews with an expert thought leader integrated into text-based elements.
Upon completion of this activity, participants should be better able to:
- Assess clinical trial data as well as the therapeutic rationale of new and emergent agents for the management of ALS
- Formulate personalized treatment plans for patients with ALS that take into account formulation options
Terry D. Heiman-Patterson, MD
Professor of Neurology
Vice Chairman of Research Department of Neurology
Director of the MDA ALS Center of Hope
Lewis Katz School of Medicine Temple University
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
- Terry D. Heiman-Patterson, MD
- Investigator Initiated Research Award: MT Pharma
- Ad Board: Amylyx, MT Pharma
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
You may immediately download your certificate.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.